[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342408-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342408-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-heterogeneity-of-signaling-pathways-and-drug-responses-in-intrahepatic-cholangiocarcinoma-with-distinct-genetic-mutations","The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations","","Intrahepatic cholangiocarcinoma (ICC) is a frequently occurring primary liver cancer with rising incidence and poor outcomes, where both intertumoral and intratumoral heterogeneity complicates effective treatment. Researchers used CRISPR/Cas9 genome-wide screening in Smad4/Pten liver-specific knockout mice to identify mutations that accelerated ICC formation. Trp53, Fbxw7, Inppl1, Tgfbr2, and Cul3 enhanced disease progression via distinct mechanisms, including PI3K-driven proliferation, immune microenvironment remodeling, cell-cycle changes, and inflammatory or signaling pathway alterations. FDA-approved drug screening in mutant organoids revealed varied responses and potential chemotherapy and targeted therapies for ICC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-heterogeneity-of-signaling-pathways-and-drug-responses-in-intrahepatic-cholangiocarcinoma-with-distinct-genetic-mutations/342408/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-heterogeneity-of-signaling-pathways-and-drug-responses-in-intrahepatic-cholangiocarcinoma-with-distinct-genetic-mutations/342408.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study on intrahepatic cholangiocarcinoma?","Question",{"text":63,"@type":64},"To determine how genetic mutations drive ICC formation and progression and how that heterogeneity affects drug responses, enabling more effective therapeutic strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mutations were found to markedly accelerate ICC formation in the mouse model?",{"text":68,"@type":64},"Mutations in Trp53, Fbxw7, Inppl1, Tgfbr2, or Cul3 were reported to markedly accelerate ICC formation in the liver-specific Smad4/Pten knockout model.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the study connect mutations to mechanisms and potential treatments?",{"text":72,"@type":64},"Transcriptome sequencing linked activated receptor tyrosine kinases and PI3K pathway upregulation to proliferation, while Cul3 notably altered the immune microenvironment and other mutations influenced the cell cycle. High-throughput screening of FDA-approved drugs in gene-mutant organoids then identified different drug responses and promising chemotherapy or targeted drug options.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342408,1790534448,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nThe heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations  \nYangyang Feng1,2,3,6, Ming Zhao 1,3,4,6, Lijian Wang1,3, Ling Li1,3, Josh Haipeng Lei1,3, Jingbo Zhou 1,3, Jinghong Chen1,3, Yumeng Wu1,3, Kai Miao1,3,5 and Chu-Xia Deng 1,2,3,5 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy among primary liver cancers, with an increasing overall incidence and poor prognosis. The intertumoral and intratumoral heterogeneity of ICC makes it difﬁcult to ﬁnd efﬁcient drug therapies. Therefore, it is essential to identify tumor suppressor genes and oncogenes that induce ICC formation and progression. Here, we performed CRISPR/Cas9-mediated genome-wide screening in a liver-speciﬁc Smad4/Pten knockout mouse model (Smad4co/co;Ptenco/co;Alb-Cre, abbreviated as SPC), which normally generates ICC after 6 months, and detected that mutations in Trp53, Fbxw7, Inppl1, Tgfbr2, or Cul3 markedly accelerated ICC formation. To illustrate the potential mechanisms, we conducted transcriptome sequencing and found that multiple receptor tyrosine kinases were activated, which mainly upregulated the PI3K pathway to induce cell proliferation. Remarkably, the Cul3 mutation stimulated cancer progression mainly by altering the immune microenvironment, whereas other mutations promoted the cell cycle. Moreover, Fbxw7, Inppl1, Tgfbr2, and Trp53 also affect inﬂammatory responses, apelin signaling, mitotic spindles, ribosome biogenesis, and nucleocytoplasmic transport pathways, respectively. We further examined FDA-approved drugs for the treatment of liver cancer and performed high-throughput drug screening of the gene-mutant organoids. Different drug responses and promising drug therapies, including chemotherapy and |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| targeted drugs, have been discovered for ICC. |  |  |\n|  | Cell Death and Disease (2024)15:34; [https://doi.org/10.1038/s41419-023-06406-7](https://doi.org/10.1038/s41419-023-06406-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nCholangiocarcinoma (CC) accounts for 10–15% of all primary liver cancers, except for hepatocellular carcinoma (HCC), and its overall incidence and mortality rates have increased in recent years [1] . CC is a biliary epithelial tumor divided into three subtypes according to its anatomical site: intrahepatic CC (ICC), perihilar CC (PCC), or distal CC (DCC) [2] . ICC is localized in the periphery of the second-order bile ducts inside the liver, whereas both PCC and DCC are located outside the liver. Mixed HCC-ICC tumors share features of HCC and ICC and present aggressive tumor growth and poor prognosis [3] . ICCs are malignant tumors and most patients are diagnosed at an advanced stage [4] . The intertumoral heterogeneity of ICC at the genomic and epigenetic levels makes it difﬁcult to ﬁnd efﬁcient therapies. Identifying the complex mechanisms of ICC formation and progression is crucial for the development of new therapeutic strategies.  \nNumerous studies have revealed genetic and epigenetic changes in ICC using integrative analytical tools. Key regulators have been shown to be mutated in CC and are related to different signaling pathways [3] . However, among patients with genomic  \nalterations, most of the identiﬁed genes had a low frequency (\u003C5%), suggesting that many of them might be passenger rather than driver mutations during ICC formation and progression [5] . However, in genomic proﬁling of 200 human CC specimens, the majority (61.5%) did not show any known mutations, suggesting that many cancer driver mutations remain unidentiﬁed [5] .  \nSmad4 is a tumor suppressor gene with frequent mutations in ICC [6] . Loss of Smad4 is lethal to embryonic development in mice; thus, a Smad4 conditional knock","cbCaiup6FQqkdvk4","https://ap.wps.com/l/cbCaiup6FQqkdvk4","pdf",14228193,13,"English","# Introduction\n## Cholangiocarcinoma overview and heterogeneity\n## Smad4 and Pten in ICC model systems\n## Prior CRISPR/Cas9 screening and new candidate analysis\n# Results (from abstract summary)\n## Accelerating ICC mutations and mechanisms\n## Pathway activation and immune microenvironment effects\n## Drug response screening in gene-mutant organoids","[{\"question\":\"What was the main goal of the study on intrahepatic cholangiocarcinoma?\",\"answer\":\"To determine how genetic mutations drive ICC formation and progression and how that heterogeneity affects drug responses, enabling more effective therapeutic strategies.\"},{\"question\":\"Which mutations were found to markedly accelerate ICC formation in the mouse model?\",\"answer\":\"Mutations in Trp53, Fbxw7, Inppl1, Tgfbr2, or Cul3 were reported to markedly accelerate ICC formation in the liver-specific Smad4/Pten knockout model.\"},{\"question\":\"How did the study connect mutations to mechanisms and potential treatments?\",\"answer\":\"Transcriptome sequencing linked activated receptor tyrosine kinases and PI3K pathway upregulation to proliferation, while Cul3 notably altered the immune microenvironment and other mutations influenced the cell cycle. High-throughput screening of FDA-approved drugs in gene-mutant organoids then identified different drug responses and promising chemotherapy or targeted drug options.\"}]","The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations | PDF",1790046482,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ac2a8beff3b1a0a88d74484a453f672.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/139d6460cea51693378c9feb9c609440.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a45d15ddbec66c3a3be731b101e2db3e.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4bd4050b36997841eff7ebdba1d96f4.webp",980,1301]